Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis
Background Fibrosing cholestatic hepatitis (FCH) is an uncommon but potentially fatal complication of recurrent hepatitis C (HCV) in liver transplant recipients. Methods We matched the treatment outcomes of 10 liver transplant recipients who developed FCH with those of 10 recipients with recurrent H...
Gespeichert in:
| Veröffentlicht in: | Clinical transplantation 2015-09, Vol.29 (9), p.813-819 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 819 |
|---|---|
| container_issue | 9 |
| container_start_page | 813 |
| container_title | Clinical transplantation |
| container_volume | 29 |
| creator | Saab, Sammy Jimenez, Melissa Bau, Sherona Goo, Tyralee Zhao, Difan Durazo, Francisco Han, Steven El Kabany, Mohammed Kaldas, Fady Tong, Myron J. Busuttil, Ronald W. |
| description | Background
Fibrosing cholestatic hepatitis (FCH) is an uncommon but potentially fatal complication of recurrent hepatitis C (HCV) in liver transplant recipients.
Methods
We matched the treatment outcomes of 10 liver transplant recipients who developed FCH with those of 10 recipients with recurrent HCV without FCH treated with sofosbuvir and ribavirin.
Results
Baseline mean alanine transaminase, aspartate transaminase, alkaline phosphatase, and total bilirubin were 186 U/L, 197 U/L, 243 U/L, and 6.7 mg/dL, respectively, in the FCH recipients and 82 U/L, 60 U/L, 110 U/L, and 0.99 mg/dL, respectively, in non‐FCH recipients. The sustained viral response in FCH and non‐FCH recipients was 40% and 80%, respectively. One‐yr patient and graft survival rates were 90% and 80%, respectively, in FCH recipients, and 100% in non‐FCH recipients. Seven FCH and six non‐FCH recipients were treated for anemia with blood transfusion and/or erythropoietin growth factors.
Conclusion
Our results suggest that the use of sofosbuvir and ribavirin is effective and tolerable in liver transplant recipients treated for recurrent FCH. There is a trend of lower sustained viral response, patient survival, and graft survival in the FCH recipients. |
| doi_str_mv | 10.1111/ctr.12584 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1710656749</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1710656749</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4334-809e3a1d723cf799093385992f8b6fa8621aff71649806d84af45b8fe151ac43</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EoqWw4AeQl7BI60fi2OwgQEEqD6FKbJAsJ7GpIW2KnVD697i0dMds5mrmzJV9ATjGqI9DDYrG9TFJeLwDupgKESGEyS7oIoFI0Ix2wIH372HKMEv2QYcwHKcEsy54HTutGjt7g8bmrvYrVUzqSvsmjAs40fPQG-thBhe2mUBfm9rn7Zd1UM1K6Gyugrazc6jgVDXFRJdhoaqlt_4Q7BlVeX206T0wvrkeZ7fR6HF4l12MoiKmNI44EpoqXKaEFiYVAglKeSIEMTxnRnFGsDImxSwWHLGSx8rESc6NxglWwaIHTte2c1d_tuHlcmp9oatKzXTdeolTjFjC0lgE9GyNFuGv3mkj585OlVtKjOQqSxmylL9ZBvZkY9vmU11uyb_wAjBYAwtb6eX_TjIbP_9ZRusL6xv9vb1Q7kOylKaJfHkYSpJdiidxxeU9_QH4_Iz0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1710656749</pqid></control><display><type>article</type><title>Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Saab, Sammy ; Jimenez, Melissa ; Bau, Sherona ; Goo, Tyralee ; Zhao, Difan ; Durazo, Francisco ; Han, Steven ; El Kabany, Mohammed ; Kaldas, Fady ; Tong, Myron J. ; Busuttil, Ronald W.</creator><creatorcontrib>Saab, Sammy ; Jimenez, Melissa ; Bau, Sherona ; Goo, Tyralee ; Zhao, Difan ; Durazo, Francisco ; Han, Steven ; El Kabany, Mohammed ; Kaldas, Fady ; Tong, Myron J. ; Busuttil, Ronald W.</creatorcontrib><description>Background
Fibrosing cholestatic hepatitis (FCH) is an uncommon but potentially fatal complication of recurrent hepatitis C (HCV) in liver transplant recipients.
Methods
We matched the treatment outcomes of 10 liver transplant recipients who developed FCH with those of 10 recipients with recurrent HCV without FCH treated with sofosbuvir and ribavirin.
Results
Baseline mean alanine transaminase, aspartate transaminase, alkaline phosphatase, and total bilirubin were 186 U/L, 197 U/L, 243 U/L, and 6.7 mg/dL, respectively, in the FCH recipients and 82 U/L, 60 U/L, 110 U/L, and 0.99 mg/dL, respectively, in non‐FCH recipients. The sustained viral response in FCH and non‐FCH recipients was 40% and 80%, respectively. One‐yr patient and graft survival rates were 90% and 80%, respectively, in FCH recipients, and 100% in non‐FCH recipients. Seven FCH and six non‐FCH recipients were treated for anemia with blood transfusion and/or erythropoietin growth factors.
Conclusion
Our results suggest that the use of sofosbuvir and ribavirin is effective and tolerable in liver transplant recipients treated for recurrent FCH. There is a trend of lower sustained viral response, patient survival, and graft survival in the FCH recipients.</description><identifier>ISSN: 0902-0063</identifier><identifier>EISSN: 1399-0012</identifier><identifier>DOI: 10.1111/ctr.12584</identifier><identifier>PMID: 26147216</identifier><language>eng</language><publisher>Denmark: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Antiviral Agents - therapeutic use ; antiviral therapy ; Case-Control Studies ; Cholestasis, Intrahepatic - drug therapy ; Cholestasis, Intrahepatic - etiology ; Cholestasis, Intrahepatic - mortality ; Drug Therapy, Combination ; Female ; fibrosing cholestatic hepatitis ; Follow-Up Studies ; Graft Survival ; hepatitis C ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - mortality ; Hepatitis C, Chronic - surgery ; Humans ; Liver Cirrhosis - drug therapy ; Liver Cirrhosis - etiology ; Liver Cirrhosis - mortality ; liver transplant ; Liver Transplantation ; Male ; Matched-Pair Analysis ; Middle Aged ; patient survival ; Postoperative Complications - drug therapy ; Postoperative Complications - mortality ; Recurrence ; Retrospective Studies ; Ribavirin - therapeutic use ; Sofosbuvir - therapeutic use ; Treatment Outcome</subject><ispartof>Clinical transplantation, 2015-09, Vol.29 (9), p.813-819</ispartof><rights>2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4334-809e3a1d723cf799093385992f8b6fa8621aff71649806d84af45b8fe151ac43</citedby><cites>FETCH-LOGICAL-c4334-809e3a1d723cf799093385992f8b6fa8621aff71649806d84af45b8fe151ac43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fctr.12584$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fctr.12584$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26147216$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saab, Sammy</creatorcontrib><creatorcontrib>Jimenez, Melissa</creatorcontrib><creatorcontrib>Bau, Sherona</creatorcontrib><creatorcontrib>Goo, Tyralee</creatorcontrib><creatorcontrib>Zhao, Difan</creatorcontrib><creatorcontrib>Durazo, Francisco</creatorcontrib><creatorcontrib>Han, Steven</creatorcontrib><creatorcontrib>El Kabany, Mohammed</creatorcontrib><creatorcontrib>Kaldas, Fady</creatorcontrib><creatorcontrib>Tong, Myron J.</creatorcontrib><creatorcontrib>Busuttil, Ronald W.</creatorcontrib><title>Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis</title><title>Clinical transplantation</title><addtitle>Clin Transplant</addtitle><description>Background
Fibrosing cholestatic hepatitis (FCH) is an uncommon but potentially fatal complication of recurrent hepatitis C (HCV) in liver transplant recipients.
Methods
We matched the treatment outcomes of 10 liver transplant recipients who developed FCH with those of 10 recipients with recurrent HCV without FCH treated with sofosbuvir and ribavirin.
Results
Baseline mean alanine transaminase, aspartate transaminase, alkaline phosphatase, and total bilirubin were 186 U/L, 197 U/L, 243 U/L, and 6.7 mg/dL, respectively, in the FCH recipients and 82 U/L, 60 U/L, 110 U/L, and 0.99 mg/dL, respectively, in non‐FCH recipients. The sustained viral response in FCH and non‐FCH recipients was 40% and 80%, respectively. One‐yr patient and graft survival rates were 90% and 80%, respectively, in FCH recipients, and 100% in non‐FCH recipients. Seven FCH and six non‐FCH recipients were treated for anemia with blood transfusion and/or erythropoietin growth factors.
Conclusion
Our results suggest that the use of sofosbuvir and ribavirin is effective and tolerable in liver transplant recipients treated for recurrent FCH. There is a trend of lower sustained viral response, patient survival, and graft survival in the FCH recipients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antiviral Agents - therapeutic use</subject><subject>antiviral therapy</subject><subject>Case-Control Studies</subject><subject>Cholestasis, Intrahepatic - drug therapy</subject><subject>Cholestasis, Intrahepatic - etiology</subject><subject>Cholestasis, Intrahepatic - mortality</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>fibrosing cholestatic hepatitis</subject><subject>Follow-Up Studies</subject><subject>Graft Survival</subject><subject>hepatitis C</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - mortality</subject><subject>Hepatitis C, Chronic - surgery</subject><subject>Humans</subject><subject>Liver Cirrhosis - drug therapy</subject><subject>Liver Cirrhosis - etiology</subject><subject>Liver Cirrhosis - mortality</subject><subject>liver transplant</subject><subject>Liver Transplantation</subject><subject>Male</subject><subject>Matched-Pair Analysis</subject><subject>Middle Aged</subject><subject>patient survival</subject><subject>Postoperative Complications - drug therapy</subject><subject>Postoperative Complications - mortality</subject><subject>Recurrence</subject><subject>Retrospective Studies</subject><subject>Ribavirin - therapeutic use</subject><subject>Sofosbuvir - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0902-0063</issn><issn>1399-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0EoqWw4AeQl7BI60fi2OwgQEEqD6FKbJAsJ7GpIW2KnVD697i0dMds5mrmzJV9ATjGqI9DDYrG9TFJeLwDupgKESGEyS7oIoFI0Ix2wIH372HKMEv2QYcwHKcEsy54HTutGjt7g8bmrvYrVUzqSvsmjAs40fPQG-thBhe2mUBfm9rn7Zd1UM1K6Gyugrazc6jgVDXFRJdhoaqlt_4Q7BlVeX206T0wvrkeZ7fR6HF4l12MoiKmNI44EpoqXKaEFiYVAglKeSIEMTxnRnFGsDImxSwWHLGSx8rESc6NxglWwaIHTte2c1d_tuHlcmp9oatKzXTdeolTjFjC0lgE9GyNFuGv3mkj585OlVtKjOQqSxmylL9ZBvZkY9vmU11uyb_wAjBYAwtb6eX_TjIbP_9ZRusL6xv9vb1Q7kOylKaJfHkYSpJdiidxxeU9_QH4_Iz0</recordid><startdate>201509</startdate><enddate>201509</enddate><creator>Saab, Sammy</creator><creator>Jimenez, Melissa</creator><creator>Bau, Sherona</creator><creator>Goo, Tyralee</creator><creator>Zhao, Difan</creator><creator>Durazo, Francisco</creator><creator>Han, Steven</creator><creator>El Kabany, Mohammed</creator><creator>Kaldas, Fady</creator><creator>Tong, Myron J.</creator><creator>Busuttil, Ronald W.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201509</creationdate><title>Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis</title><author>Saab, Sammy ; Jimenez, Melissa ; Bau, Sherona ; Goo, Tyralee ; Zhao, Difan ; Durazo, Francisco ; Han, Steven ; El Kabany, Mohammed ; Kaldas, Fady ; Tong, Myron J. ; Busuttil, Ronald W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4334-809e3a1d723cf799093385992f8b6fa8621aff71649806d84af45b8fe151ac43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antiviral Agents - therapeutic use</topic><topic>antiviral therapy</topic><topic>Case-Control Studies</topic><topic>Cholestasis, Intrahepatic - drug therapy</topic><topic>Cholestasis, Intrahepatic - etiology</topic><topic>Cholestasis, Intrahepatic - mortality</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>fibrosing cholestatic hepatitis</topic><topic>Follow-Up Studies</topic><topic>Graft Survival</topic><topic>hepatitis C</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - mortality</topic><topic>Hepatitis C, Chronic - surgery</topic><topic>Humans</topic><topic>Liver Cirrhosis - drug therapy</topic><topic>Liver Cirrhosis - etiology</topic><topic>Liver Cirrhosis - mortality</topic><topic>liver transplant</topic><topic>Liver Transplantation</topic><topic>Male</topic><topic>Matched-Pair Analysis</topic><topic>Middle Aged</topic><topic>patient survival</topic><topic>Postoperative Complications - drug therapy</topic><topic>Postoperative Complications - mortality</topic><topic>Recurrence</topic><topic>Retrospective Studies</topic><topic>Ribavirin - therapeutic use</topic><topic>Sofosbuvir - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saab, Sammy</creatorcontrib><creatorcontrib>Jimenez, Melissa</creatorcontrib><creatorcontrib>Bau, Sherona</creatorcontrib><creatorcontrib>Goo, Tyralee</creatorcontrib><creatorcontrib>Zhao, Difan</creatorcontrib><creatorcontrib>Durazo, Francisco</creatorcontrib><creatorcontrib>Han, Steven</creatorcontrib><creatorcontrib>El Kabany, Mohammed</creatorcontrib><creatorcontrib>Kaldas, Fady</creatorcontrib><creatorcontrib>Tong, Myron J.</creatorcontrib><creatorcontrib>Busuttil, Ronald W.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saab, Sammy</au><au>Jimenez, Melissa</au><au>Bau, Sherona</au><au>Goo, Tyralee</au><au>Zhao, Difan</au><au>Durazo, Francisco</au><au>Han, Steven</au><au>El Kabany, Mohammed</au><au>Kaldas, Fady</au><au>Tong, Myron J.</au><au>Busuttil, Ronald W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis</atitle><jtitle>Clinical transplantation</jtitle><addtitle>Clin Transplant</addtitle><date>2015-09</date><risdate>2015</risdate><volume>29</volume><issue>9</issue><spage>813</spage><epage>819</epage><pages>813-819</pages><issn>0902-0063</issn><eissn>1399-0012</eissn><abstract>Background
Fibrosing cholestatic hepatitis (FCH) is an uncommon but potentially fatal complication of recurrent hepatitis C (HCV) in liver transplant recipients.
Methods
We matched the treatment outcomes of 10 liver transplant recipients who developed FCH with those of 10 recipients with recurrent HCV without FCH treated with sofosbuvir and ribavirin.
Results
Baseline mean alanine transaminase, aspartate transaminase, alkaline phosphatase, and total bilirubin were 186 U/L, 197 U/L, 243 U/L, and 6.7 mg/dL, respectively, in the FCH recipients and 82 U/L, 60 U/L, 110 U/L, and 0.99 mg/dL, respectively, in non‐FCH recipients. The sustained viral response in FCH and non‐FCH recipients was 40% and 80%, respectively. One‐yr patient and graft survival rates were 90% and 80%, respectively, in FCH recipients, and 100% in non‐FCH recipients. Seven FCH and six non‐FCH recipients were treated for anemia with blood transfusion and/or erythropoietin growth factors.
Conclusion
Our results suggest that the use of sofosbuvir and ribavirin is effective and tolerable in liver transplant recipients treated for recurrent FCH. There is a trend of lower sustained viral response, patient survival, and graft survival in the FCH recipients.</abstract><cop>Denmark</cop><pub>Blackwell Publishing Ltd</pub><pmid>26147216</pmid><doi>10.1111/ctr.12584</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-0063 |
| ispartof | Clinical transplantation, 2015-09, Vol.29 (9), p.813-819 |
| issn | 0902-0063 1399-0012 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1710656749 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Aged Antiviral Agents - therapeutic use antiviral therapy Case-Control Studies Cholestasis, Intrahepatic - drug therapy Cholestasis, Intrahepatic - etiology Cholestasis, Intrahepatic - mortality Drug Therapy, Combination Female fibrosing cholestatic hepatitis Follow-Up Studies Graft Survival hepatitis C Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - mortality Hepatitis C, Chronic - surgery Humans Liver Cirrhosis - drug therapy Liver Cirrhosis - etiology Liver Cirrhosis - mortality liver transplant Liver Transplantation Male Matched-Pair Analysis Middle Aged patient survival Postoperative Complications - drug therapy Postoperative Complications - mortality Recurrence Retrospective Studies Ribavirin - therapeutic use Sofosbuvir - therapeutic use Treatment Outcome |
| title | Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T12%3A35%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treating%20fibrosing%20cholestatic%20hepatitis%20C%20with%20sofosbuvir%20and%20ribavirin:%20a%20matched%20analysis&rft.jtitle=Clinical%20transplantation&rft.au=Saab,%20Sammy&rft.date=2015-09&rft.volume=29&rft.issue=9&rft.spage=813&rft.epage=819&rft.pages=813-819&rft.issn=0902-0063&rft.eissn=1399-0012&rft_id=info:doi/10.1111/ctr.12584&rft_dat=%3Cproquest_cross%3E1710656749%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1710656749&rft_id=info:pmid/26147216&rfr_iscdi=true |